Gemini Therapeutics (NASDAQ:GMTX) Trading 0.1% Higher - Here's What Happened

Key Points

• During mid-day trading Friday, Gemini Therapeutics (GMTX) was up 0.1%, last at $59.17 with volume of ~452,879 shares (a 139% increase vs. average), and is trading below its 50-day and 200-day SMAs of $69.57 and $75.62.
• Gemini is a clinical-stage biotechnology company developing integrin-targeting antibodies to block TGF-β–driven fibrosis, with lead programs focused on chronic kidney disease and idiopathic pulmonary fibrosis and a market cap of about $2.56 billion.

Gemini Therapeutics, Inc. (NASDAQ:GMTX - Get Free Report)'s stock price rose 0.1% during mid-day trading on Friday . The company traded as high as $60.39 and last traded at $59.17. Approximately 452,879 shares were traded during trading, an increase of 139% from the average daily volume of 189,291 shares. The stock had previously closed at $59.1350.

Gemini Therapeutics Stock Performance

The firm has a market cap of $2.56 billion, a P/E ratio of -59.17 and a beta of -0.12. The firm has a 50 day simple moving average of $69.57 and a 200 day simple moving average of $75.62.

About Gemini Therapeutics

Gemini Therapeutics NASDAQ: GMTX is a clinical‐stage biotechnology company focused on the discovery and development of integrin‐targeting therapies for fibrotic diseases. Leveraging a proprietary antibody discovery platform, Gemini identifies and optimizes highly selective inhibitors of integrin subunits that play a key role in activating transforming growth factor‐β (TGF-β), a central driver of tissue fibrosis. The company's approach is designed to block fibrotic signaling at its source, potentially offering improved safety and efficacy profiles compared with broader anti‐fibrotic agents.

Gemini's lead programs are directed toward chronic kidney disease and idiopathic pulmonary fibrosis, two areas with significant unmet medical need and limited treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.